» Articles » PMID: 8723765

Productive and Non-productive Binding of Botulinum Neurotoxin A to Motor Nerve Endings Are Distinguished by Its Heavy Chain

Overview
Journal J Neurosci Res
Specialty Neurology
Date 1996 May 1
PMID 8723765
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Botulinum neurotoxin type A, a di-chain protein produced by Clostridium botulinum and responsible for botulism, blocks acetylcholine release from peripheral nerves by binding to the terminals, undergoing internalization and proteolyzing a protein essential for exocytosis. As butolinum neurotoxin is being used clinically for the treatment of dystonias and certain spasticities, deciphering the details of its specific targeting to cholinergic nerve endings has assumed great importance. Thus, interaction of butolinum neurotoxin type A with murine motor nerve terminals-a prime target in vivo-was investigated. Autoradiographic analysis revealed saturable, high-affinity interaction of radioiodinated toxin (0.4 nM) with two ecto-acceptor types, distinguished by an excess of the toxin's heavy chain which prevented only a fraction of this binding. Botulinum neurotoxin was also biotinylated through its free sulfhydryl groups, known not to be essential for neurotoxicity. Similar binding of this active derivative was, likewise, partially blocked by heavy chain, confirming the above results. This binding that is resistant to heavy chain equates to botulinum neurotoxin interacting with productive ecto-acceptors, leading to delivery to its cytosolic site of action, because heavy chain proved unable to antagonize toxin-induced neuromuscular paralysis. In contrast, it is deduced that botulinum neurotoxin bound to heavy chain-susceptible sites has a different fate, presumably due to trafficking via another route, and thus would be inefficient in causing neuroparalysis.

Citing Articles

Endomicroscopy and electromyography of neuromuscular junctions in situ.

Brown R, Dissanayake K, Skehel P, Ribchester R Ann Clin Transl Neurol. 2014; 1(11):867-83.

PMID: 25540801 PMC: 4265058. DOI: 10.1002/acn3.124.


Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.

Restani L, Giribaldi F, Manich M, Bercsenyi K, Menendez G, Rossetto O PLoS Pathog. 2013; 8(12):e1003087.

PMID: 23300443 PMC: 3531519. DOI: 10.1371/journal.ppat.1003087.


Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Gul N, Smith L, Ahmed S PLoS One. 2010; 5(9):e12872.

PMID: 20877571 PMC: 2943925. DOI: 10.1371/journal.pone.0012872.


An efficient drug delivery vehicle for botulism countermeasure.

Zhang P, Ray R, Singh B, Li D, Adler M, Ray P BMC Pharmacol. 2009; 9:12.

PMID: 19860869 PMC: 2774289. DOI: 10.1186/1471-2210-9-12.


Onset dynamics of type A botulinum neurotoxin-induced paralysis.

Lebeda F, Adler M, Erickson K, Chushak Y J Pharmacokinet Pharmacodyn. 2008; 35(3):251-67.

PMID: 18551355 PMC: 2798021. DOI: 10.1007/s10928-008-9087-3.